Article Text

PDF

Extended report
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
  1. D A Isenberg1,
  2. M Petri2,
  3. K Kalunian3,
  4. Y Tanaka4,
  5. M B Urowitz5,
  6. R W Hoffman6,
  7. M Morgan-Cox6,
  8. N Iikuni6,
  9. M Silk6,
  10. D J Wallace7
  1. 1University College Hospital to University College London, London, UK
  2. 2Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  3. 3Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, California, USA
  4. 4The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
  5. 5University of Toronto, Toronto Western Hospital, Toronto, Canada
  6. 6Eli Lilly and Company, Indianapolis, Indiana, USA
  7. 7Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California, USA
  1. Correspondence to Professor David A Isenberg, Room 424 The Rayne Building, University College London, 5 University Street, London WC1E 6JF, UK; d.isenberg{at}ucl.ac.uk

Abstract

Objectives Evaluate efficacy and safety of tabalumab, a human IgG4 monoclonal antibody that binds and neutralises membrane and soluble B-cell activating factor (BAFF) versus placebo plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE).

Methods This phase III, 52-week study randomised 1164 patients with moderate-to-severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index ≥6 at baseline). Patients received SoC plus subcutaneous injections of tabalumab or placebo, starting with a loading dose (240 mg) at week 0 and followed by 120 mg every two weeks (120 Q2W, n=387), 120 mg every four weeks (120 Q4W, n=389) or placebo Q2W (n=388). Primary endpoint: proportion of patients achieving SLE Responder Index 5 (SRI-5) response at week 52.

Results Similar proportions of patients in each group achieved SRI-5 response at week 52 (120 Q2W: 31.8%; 120 Q4W: 35.2% and placebo: 29.3%). Key secondary endpoints were not met. In a sensitivity analysis not excluding patients who decreased antimalarials or immunosuppressants, SRI-5 response was achieved with 120 Q4W (37.0% vs 29.8% placebo; p=0.021), but not 120 Q2W (34.1%; p=0.171). Significant reductions in anti-dsDNA antibodies, increases in C3 and C4, and reductions in total B cells and immunoglobulins were observed with tabalumab. No differences were observed between treatment groups in percentage of deaths (120 Q2W: 0.8%; 120 Q4W: 0.5%; placebo: 0.5%), serious adverse events (AEs) (range 11.1–14.4%) or treatment-emergent AEs (range 81.1–82.3%).

Conclusions Tabalumab had biological activity—changes in anti-dsDNA, complement, B cells and immunoglobulins—consistent with BAFF pathway inhibition. Key clinical efficacy endpoints did not achieve statistical significance. Safety profiles were similar with tabalumab and placebo.

Trial registration number NCT01196091.

  • Autoimmune Diseases
  • B cells
  • Disease Activity
  • Systemic Lupus Erythematosus

Statistics from Altmetric.com

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease with an estimated prevalence of 7–160 cases in 100 000 worldwide.1 ,2 Mortality has improved, probably due to faster and more accurate diagnosis, increased disease awareness, more appropriate use of corticosteroids and cytotoxic/immunosuppressive drugs, and a greater focus on treatment of comorbidities. However, few drugs are approved for the treatment of SLE, and a substantial unmet medical need remains.

There is compelling evidence that B cells are involved in the etiopathogenesis of SLE. B cells may be blocked directly by antibodies to CD20 or CD22, or via blockade of vital B-cell survival factors (B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL)).3–5 BAFF is a tumour necrosis factor family ligand that is important for B-cell development, survival and differentiation.6–8 BAFF serum is elevated in patients with SLE and correlate with autoantibody production and disease activity.9 ,10 Thus, targeting B cells by neutralising BAFF may suppress SLE disease activity. Tabalumab is a fully human IgG4 monoclonal antibody, administered subcutaneously, that binds and neutralises both membrane and soluble BAFF. Two phase III studies, ILLUMINATE-1 and ILLUMINATE-2, evaluated the efficacy and safety of subcutaneous doses of tabalumab plus standard of care (SoC) versus placebo plus SoC in patients with active SLE. We present ILLUMINATE-1 results.

Methods

Study design

Patients in ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study, were randomly assigned 1:1:1 (stratified by anti-dsDNA positivity and African descent) to receive subcutaneous tabalumab 120 mg every two weeks (Q2W) plus SoC (120 Q2W), tabalumab 120 mg every four weeks (Q4W) plus SoC (120 Q4W; administered by alternating 120 mg tabalumab and placebo injections Q2W), or placebo Q2W plus SoC. At week 0, the tabalumab groups received a 240 mg loading dose (2×120 mg injection) and the placebo group received two placebo injections. Blinded treatments were administered from week 0 through 50. After week 52, patients discontinued study drug and entered safety follow-up or entered a multiyear, open-label, safety extension study of tabalumab. Data from the double-blind, 52-week period are included in this report.

Patients were allowed to continue SoC for SLE, including non-steroidal anti-inflammatory drugs (unrestricted), corticosteroids, stable doses of antimalarials (such as chloroquine or hydroxychloroquine) and/or stable doses of immunosuppressants (such as azathioprine, methotrexate, mycophenolate, cyclophosphamide or cyclosporine). Increases or decreases in corticosteroid dose were allowed during the first 24 weeks, after which the dose had to be less than or equal to the baseline dose, and only reductions were allowed thereafter. No added, increases in or decreases in antimalarials or immunosuppressants were allowed at any time.

Entry criteria

Eligible patients were 18 years or older and had a diagnosis of SLE (fulfilled 4/11 American College of Rheumatology revised criteria),11 a positive antinuclear antibody (HEp-2 ANA; titre ≥1:80) test by the central laboratory during screening (patients with negative ANA, but positive anti-dsDNA, were retested before being excluded), and a Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index (SELENA-SLEDAI) score ≥612 (see online supplementary text).

Endpoints

The primary endpoint was the proportion of patients achieving an SLE Responder Index 5 (SRI-5) response at week 52. The SRI-5 is a composite endpoint defined as ≥5 point improvement (reduction) in SELENA-SLEDAI score, no new British Isles Lupus Assessment Group (BILAG) 2004 index score of A or no more than one new BILAG B score, and no worsening (increase ≥0.3 points from baseline) in physician's global assessment (PGA).13 Patients who did not meet all three clinical criteria, who added, increased or decreased antimalarial or immunosuppressant treatment, who could not adhere to corticosteroid-dosing requirements and/or who discontinued study prior to week 52 were considered non-responders.

Key secondary endpoints included time to first severe SLE flare on the SELENA-SLEDAI Flare Index,14 proportion of patients with reduction in corticosteroid dose by ≥25% to ≤7.5 mg/day prednisone (or equivalent) for ≥3 consecutive months from weeks 24 through 52, and change from baseline on the Brief Fatigue Inventory at week 52.15 ,16

Other endpoints included change in proportion of SRI-5 responders over time; individual components of SRI-5; the proportion of patients achieving SRI-4 and SRI-6 through SRI-10 at week 52; and mean changes in SELENA-SLEDAI, PGA, Systemic Lupus Erythematosus Disease Activity Index 2000, Systemic Lupus International Collaborating Clinics (SLICC) damage index and disease-related biomarkers (anti-dsDNA, C3 and C4) at week 52. A medical team reviewed efficacy endpoint data for consistency. Serum tabalumab concentrations, changes in pharmacodynamic markers (total B cells, B-cell subsets, mean BAFF levels and immunoglobulin concentrations), on the Columbia-Suicide Severity Rating Scale and on the Quick Inventory of Depressive Symptomatology (QIDS-SR16), and other safety assessments (serious adverse events (SAEs), treatment-emergent AEs (TEAEs), AEs of special interest, vital signs, clinical laboratory data) were analysed (see online supplementary text).

Statistical analysis

All analyses of efficacy, serum tabalumab concentrations and biological activity were conducted on the intent-to-treat population. Safety analyses were applied to the safety population (patients who received ≥1 dose of study drug). For the primary endpoint (SRI-5), a sample size of 380 patients per group was predicted to provide >95% power to detect a statistically significant difference of ≥14% between the tabalumab and placebo groups. Statistical methods used a two-sided, 0.05 significance level and included logistic regression for binary efficacy variables, Cox proportional hazard model for time-to-event variables, Fisher's exact for discrete variables and mixed-effects model for repeated measures or analysis of covariance for continuous variables. A graphical approach for multiple comparisons was used to control the overall type I error in analysis of primary and key secondary endpoints. Additional analyses were performed to identify baseline characteristics associated with responders at week 52 and to evaluate how response to tabalumab relative to placebo varied across different categories within a subgroup. Analyses of efficacy variables were adjusted for randomisation stratification factors (anti-dsDNA status and race) and region. For all non-SRI continuous measures, a last observation carried forward (LOCF) approach was used.

Results

Patient disposition and baseline characteristics

Of the 1164 randomised patients, ≥75% in each group completed the 52-week trial (figure 1). Discontinuation rates and reasons for early discontinuation were similar across groups. Baseline demographics, SLE disease activity and medications were generally balanced across groups (table 1).

Table 1

Baseline demographics and clinical characteristics

Figure 1

Flow diagram of patient disposition during the study. aPatients from two study sites were not included in the intent-to-treat (ITT) population due to violations at the study site. AE, adverse event; Q2W, every two weeks; Q4W, every four weeks.

Efficacy

The primary endpoint, SRI-5 response at week 52, was not achieved in either treatment group (figure 2A, table 2). At week 52, SRI-5 (non-responder imputation (NRI)) response rates were 31.8% in the 120 Q2W and 35.2% in the 120 Q4W group versus 29.3% in the placebo group (p>0.05, each comparison). For all three components of SRI, the percentages of responders were higher in the tabalumab groups versus placebo (table 2). See online supplementary table S1 for specific SELENA-SLEDAI organ improvement.

Table 2

Clinical and biomarker outcomes

Figure 2

Clinical outcomes. (A) SLE Responder Index 5 (SRI-5) response rates over the 52-week treatment period. Primary endpoint analysis included patients who achieved SRI-5 endpoint without violating the concomitant medication rules. Patients who did not meet all three clinical criteria, who added, increased or decreased antimalarial or immunosuppressant treatment, who could not meet the corticosteroid-dosing requirements and/or who discontinued the study prior to week 52 were considered non-responders. p Value based on odds ratio estimated from logistic regression model. (B) SRI-4 through SRI-10 response rates at week 52. Predefined analyses of SRI endpoints described above used a modified concomitant medication rule where patients who decreased their antimalarials or immunosuppressants during the study were not automatic non-responders. SRI-6 through SRI-10 performed in subset of patients who entered study with Safety of Estrogens in Lupus Erythematosus National Assessment—SLE Disease Activity Index (SELENA-SLEDAI)≥6-SELENA-SLEDAI≥10, respectively. *p≤0.05 vs placebo; **p≤0.001 vs placebo. Symbols in greyscale represent 52-week endpoint data calculated using a non-responder imputation (NRI), circle=120 every two weeks (Q2W), square=120 every four weeks (Q4W) and triangle = placebo.

None of the key secondary endpoints (ie, time to first severe SLE flare, corticosteroid-sparing effects and change from baseline in worst level of fatigue) were significantly different with tabalumab versus placebo (table 2). At week 52, the changes in SELENA-SLEDAI scores were also similar in the 120 Q2W (least-squares (LS) mean: −5.1), 120 Q4W (LS mean: −5.4) and placebo groups (LS mean: −5.2).

In a predefined sensitivity analysis of the primary endpoint, where patients who decreased their antimalarials or immunosuppressants during the study were not automatic non-responders17 SRI-5 (NRI) response rates were 34.1% in the 120 Q2W (p=0.171) and 37.0% in the 120 Q4W group (p=0.021) versus 29.8% in the placebo group at week 52 (figure 2B). In the same predefined analyses of SRI-4 and SRI-6 through SRI-10, both the 120 Q2W (47.2%) and 120 Q4W groups (47.4%) had a significantly higher percentage of SRI-4 responders at week 52 versus placebo (39.8%; p≤0.05, both comparisons), and significantly more 120 Q4W patients achieved SRI-6 response versus placebo (35.3% vs 29.2%, p=0.044) at week 52.

The effect of tabalumab was also evaluated in patients who were anti-dsDNA positive and who had low C3 and C4 levels at baseline. There was no significant difference between tabalumab and placebo in percentage of SRI-5 responders at week 52 (120 Q2W: 34.1%, 120 Q4W: 32.3%, placebo: 35.4%; p>0.05, each comparison).

The anti-dsDNA levels decreased significantly in both tabalumab groups versus placebo as early as week 4 (figure 3) and continued to decrease and remained well below baseline levels through week 52 (LS mean changes, 120 Q2W: −25.60 IU; 120 Q4W: −22.28 IU; placebo: −4.13 IU; p<0.001, each comparison). Of the patients with anti-dsDNA ≥30 IU/mL (positive) at baseline, 14% in 120 Q2W and 16% in 120 Q4W versus 9% in placebo returned to normal levels (<30 IU/mL) at week 52.

Figure 3

Mean change in anti-dsDNA over the 52-week treatment period. *p≤0.05 vs placebo; **p≤0.001 vs placebo. LS, least squares; Q2W, every two weeks; Q4W, every four weeks.

Increases in C3 and C4 were observed in both tabalumab groups versus placebo at week 52 (table 2). Of the patients with low complement C3 and/or C4 at baseline, 29% in 120 Q2W and 36% in the 120 Q4W group versus 22% in the placebo group had normalised at week 52.

Other than sex, there were no baseline variables (ie, age, region, anti-dsDNA status, complement, race, ethnicity, disease severity (SELENA-SLEDAI <10 or ≥10), mucocutaneous or musculoskeletal organ involvement, PGA score, SLICC score, severe seropositivity, concomitant medication use, number of prior treatment failures, comorbidities, time since onset of SLE or BAFF concentration) for which the treatment effect differed across subgroups.

Pharmacodynamics

At week 52, tabalumab treatment was associated with increases in median BAFF concentrations from baseline (120 Q2W: 95349 pg/mL; 120 Q4W: 91332 pg/mL); as expected, these increases were significantly different from changes observed in the placebo group (27 pg/mL, p<0.001, both comparisons) due to presence of active drug binding to BAFF. In the tabalumab groups, median total B-cell counts initially increased from baseline at week 1 (120 Q2W: 64.5 cells/µL; 120 Q4W: 70.0 cells/µL; placebo: −1.0 cells/µL; p<0.001, each comparison) and subsequently decreased below baseline values through week 52 (LOCF) (120 Q2W: −68.0 cells/µL; 120 Q4W: −57.0 cells/µL; placebo: −7.5 cells/µL; p<0.001, each comparison) (see online supplementary figure S1A). B-cell subset changes in both tabalumab groups were significantly different from placebo; however, there was no clear dose separation in either tabalumab group. The largest magnitude of change for B cells was the reduction in the mature naive subset. No significant T-cell changes were observed. Statistically significant decreases in serum immunoglobulins were observed at each time point over the 52-week treatment period (see online supplementary figure S1 B,D). However, the number of patients who dropped below normal range was low in the 120 Q2W, 120 Q4W and placebo groups; IgA: 2 (0.5%), 4 (1.1%) and 2 (0.5%); IgG: 4 (1.1%), 2 (0.5%) and 2 (0.5%); and IgM: 64 (18.6%), 52 (15.2%) and 14 (4.0%), respectively.

Pharmacokinetics

Analysis of the pharmacokinetic data indicated that tabalumab concentrations shifted higher for the tabalumab 120 Q2W group. Pharmacokinetic analysis also showed an overlap between the two dosing regimens, as expected (data not shown).

Safety and tolerability

No clinically meaningful or significant differences in the number of deaths, frequency of SAEs or TEAEs, or number of patients who discontinued due to an AE were observed between groups (table 3). The majority of TEAEs were mild-to-moderate. Ten pregnancies were reported during the treatment period (table 3), five of which were carried to term and there were no fetal abnormalities at birth (one in 120 Q2W, one in placebo, three in 120 Q4W). Two fetal deaths in utero (one placebo patient with preeclampsia and one patient in 120 Q2W group), one spontaneous abortion (placebo) and one terminated pregnancy (placebo) were reported; and one pregnant patient was lost to follow-up (120 Q2W).

Table 3

Safety and tolerability

The incidences of serious infections and severe infections were similar in the tabalumab and placebo groups (table 3). The incidences of opportunistic infections of interest were herpes zoster, reported in 13 patients (3.4%) in 120 Q2W, 4 (1.0%) in 120 Q4W and 10 (2.6%) in placebo; disseminated tuberculosis, reported in 1 patient (0.3%) in 120 Q2W; and cytomegalovirus, reported in 1 patient (0.3%) in 120 Q4W. Oral candidiasis was reported in six (1.6%) patients in 120 Q2W, three (0.8%) in 120 Q4W and eight (2.1%) in placebo; however, no unexpected fungal opportunistic infections were reported. There were no differences in the percentages of patients reporting an injection-site reaction, in the incidences of adjudicated major adverse cardiovascular events or in reported malignancies. No anaphylactic events were reported; hypersensitivity reactions occurred in five patients in 120 Q2W, one patient in 120 Q4W and two patients in placebo.

There were no differences in the percentages of patients in the tabalumab groups versus placebo who reported depression, treatment-emergent suicidal ideation or suicidal behaviour during the treatment period (table 3). The change from baseline in the QIDS-SR16 score at week 52 (LOCF) was similar in the tabalumab and placebo groups.

No clinically meaningful differences in laboratory abnormalities were noted. The frequency of treatment-emergent antidrug antibodies was low, and no positive neutralising antidrug antibodies were identified (table 3).

Discussion

This phase III, placebo-controlled study in patients with active, moderate-to-severe SLE assessed the efficacy of tabalumab 120 Q2W or 120 Q4W versus placebo. The primary endpoint, SRI-5 response, was not met for either dose group, though 120 Q4W showed a trend towards improvement versus placebo at week 52 (p=0.052).

Statistical significance was not achieved on secondary measures of clinical efficacy (ie, time to first severe flare, corticosteroid-sparing effects, fatigue and individual components of the SRI). However, a significant pharmacodynamic effect (ie, anti-dsDNA reductions, C3 and C4 increases) was observed in the tabalumab groups. In a flare prevention trial, patients administered atacicept (a fusion protein that blocks B-lymphocyte stimulator and APRIL) showed marked anti-dsDNA reductions and C3 increases, although only patients receiving the higher dose demonstrated any clinical benefit.18 The reasons for the difference are not obvious. One could speculate that some form of ‘threshold effect’ is taking place. In general, biomarkers often perform rather variably in their relationship with clinical disease. Based on clinical observations from this trial and ILLUMINATE-2,17 a similarly designed phase III, global study of tabalumab where the SRI-5 endpoint was met and a dose-effect was observed, it remains possible that higher doses or more frequent dosing may lead to better efficacy despite maximal effect on pharmacodynamic markers.

Significant increases in BAFF concentrations, reductions in total B cells and reductions in immunoglobulins were also observed in the tabalumab groups. These changes were consistent with tabalumab's mechanism of action and with previous studies.19–21 Increases in BAFF concentration were expected. In the presence of tabalumab, BAFF concentration increases because the anti-BAFF Ig molecule (tabalumab) binds to BAFF creating a BAFF-anti-BAFF Ig complex. The measurable level of BAFF accumulated in the presence of tabalumab. Overall, these outcomes were indicative of biological activity consistent with BAFF inhibition.

Baseline BAFF concentrations were not predictive of higher SRI response rates with tabalumab. A study evaluating whether serum BAFF levels correlate with SLE relapse or remission following B-cell-depleting therapy demonstrated that patients were more likely to flare when serum BAFF was rising.22 However, serum BAFF level did not predict subsequent remission or relapse after treatment. Despite being a strong correlate of flares, baseline BAFF concentrations may not be a strong indicator of response to B-cell-targeting therapies.

In a predefined sensitivity analysis of the primary endpoint, where patients who decreased antimalarials or immunosuppressants were not automatically non-responders, SRI-5 response was met with 120 Q4W (37.0% vs 29.8% placebo), but not the more frequent 120 Q2W dose (34.1%). In similar analyses of SRI-4 and SRI-6 through SRI-10, both the 120 Q2W (47.2%) and 120 Q4W groups (47.4%) had a significantly higher SRI-4 response than placebo (39.8%) and the 120 Q4W group also had a higher SRI-6 response (35.3% vs 29.2% placebo). The ILLUMINATE-2 primary endpoint applied the same concomitant medication rules noted above and SRI-5 response was met with the more frequent 120 Q2W dose, but not 120 Q4W.18 Additionally, 120 Q2W also had a significantly higher percentage of responders than placebo when using other SRI cut-offs (ie, SRI-4, SRI-6, SRI-7, SRI-9 and SRI-10).

Belimumab is a monoclonal antibody that targets soluble BAFF and has been approved for the treatment of SLE in a number of countries.23 ,24 Tabalumab is a monoclonal antibody that targets both membrane and soluble BAFF. Beyond the differences in mechanism of action, there are no data that further differentiate the biological activity of these drugs. In two phase III trials of belimumab, 43% and 58% of patients, respectively, receiving belimumab 10 mg/kg plus SoC achieved the primary endpoint of SRI-4 (vs 33% and 44%, placebo).25 ,26 Unlike the ILLUMINATE-1 study, the belimumab trials allowed the addition of new antimalarial treatments and increases in immunosuppressants up to week 16, and corticosteroid use was less restrictive. Despite similarities in trial design, it is difficult to determine if any dissimilarities in baseline variables, background medications or mechanism of action had an impact on the different study outcomes.

The safety data show no unexpected events and low levels of antidrug antibody. Although a higher incidence of herpes zoster in the Q2W group was noted, there were no other indications of opportunistic infection. Overall, there was no increased risk of mortality, or of serious, severe adverse effects with tabalumab relative to placebo.

This study enrolled patients that principally had joint and skin manifestations, which may limit applicability of the results to the broader, more heterogeneous features of SLE. In addition, variations in clinical practices worldwide were indicated by a relatively small percentage of patients (∼63%) taking an antimalarial at baseline as well as other differences in SoC. Although baseline variables were balanced across groups, it is possible that differences in SoC may also represent differences in degrees of illness or a patient's responsiveness to treatment. Additionally, in the absence of mild-or-moderate flare analyses, the impact of treatment on flares of lesser severity is unknown.

Tabalumab did not meet the primary endpoint, SRI-5 response, or key secondary endpoints, despite pharmacodynamic evidence of biological activity that was consistent with BAFF pathway inhibition. Safety profiles of the tabalumab groups were similar to placebo with no unexpected signals.

Acknowledgments

The authors would like to thank all of the ILLUMINATE-1 investigators for their participation, Dr Pierre-Yves Berclaz of Eli Lilly and Company (Indianapolis, IN) for assistance with trial design and execution, Rebecca Taha, Steven Watts, Tammy Forrester and Allen Nyhuis of Eli Lilly and Company (Indianapolis, IN) for assistance with statistical analyses, and Kelly Guerrettaz and Cindi Wood of inVentiv Health Clinical (Princeton, NJ) for assistance with manuscript writing and editing, respectively.

References

View Abstract
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Lay summary

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Handling editor Tore K Kvien

  • Contributors DAI, MBU and KK have participated in the analysis and interpretation of data and drafting and/or critical revision of the manuscript. YT has participated in study conception and design, acquisition of data, analysis and interpretation of the data and critical revision of the manuscript. MM-C has participated in study conception and design, statistical analysis and interpretation of data, and critical revision of the manuscript. MP, RWH, NI, MS and DJW have participated in study conception and design, analysis and interpretation of the data, and drafting and/or critical revision of the manuscript.

  • Funding Eli Lilly and Company.

  • Competing interests DAI has acted as a consultant for Eli Lilly and Company. The honoraria offered are passed to a local arthritis charity. MP has acted as a consultant for Eli Lilly and Company. KK has acted as a consultant for Eli Lilly and Company. YT has received consulting fees, speaking fees and/or honoraria from AbbVie, Daiichi-Sankyo, Chugai, Takeda, Mitsubishi-Tanabe, Bristol-Myers, Astellas, Eisai, Janssen, Pfizer, Asahi-kasei, Eli Lilly and Company, GlaxoSmithKline, UCB, Teijin, MSD, Santen and has received research grants from Mitsubishi-Tanabe, Takeda, Chugai, Astellas, Eisai, Taisho-Toyama, Kyowa-Kirin, AbbVie, Bristol-Myers. MBU has acted as a consultant for Eli Lilly and Company. RWH, MM-C, NI and MS are employees of and are shareholders in Eli Lilly and Company. DJW has acted as a consultant for Eli Lilly and Company.

  • Patient consent Obtained.

  • Ethics approval The protocol was approved by each institutional review board subject to applicable laws and regulations and ethical principles consistent with the Declaration of Helsinki.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles